KROS(Keros Therapeutics, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $20.10M | $0 | $151.00K | $3.55M | $243.86M |
| 毛利润 | — | — | — | — | — |
| 营业利润 | −$56.37M | −$114.79M | −$169.94M | −$210.83M | $67.57M |
| 净利润 | −$58.74M | −$104.68M | −$152.99M | −$187.35M | $87.01M |
| 经营现金流 | −$62.15M | −$70.06M | −$124.51M | −$160.87M | $107.50M |
| 自由现金流 | −$63.17M | −$71.30M | −$126.97M | −$162.80M | $105.95M |
| 摊薄每股收益 | $-2.52 | $-4.15 | $-5.20 | $-5.00 | $2.30 |